Hyperandrogenism syndrome: diagnostics and treatment from the position of clinical endocrinology

Main Article Content

M.R. Mykytyuk
O.O. Khyzhnyak

Abstract

Hyperandrogenism, a pathological condition caused by the effect of excess production of androgens on target organs and tissues, is one of the most common hormonal disorders observed in 5–20 % of women of reproductive age in the population and in 35–41 % of women suffering from infertility due to chronic ano­vulation. Hyperandrogenism is manifested by a combination of signs of damage to the skin and its appendages (seborrhea, acne, hirsutism, alopecia) and is defined by the term androgen-dependent dermopathy. In combination with other manifested signs of virilization, hyperandrogenism greatly aggravates socio-psychological, interpersonal relationships in most patients, often cau­sing anxiety, depression, and a decrease in the quality of life. In this regard, the problem of hyperandrogenism is not only of medical but also of social significance. An urgent problem, widely studied by both endocrinologists and gynecologists, is a clinical variant of hyperandrogenism syndrome such as polycystic ovary syndrome. The article presents a discussion of the National Consensus on the management of patients with hyperandrogenism (2016), makes proposals and additions to the diagnosis and management of patients with syndromic forms of hyperandrogenism (pubertal dyspituitarism and its equivalent in adults — hypothalamic-pituitary dysfunction, nonclassical form of congenital dysfunction of the cortex adrenal glands). The key positions concerning the assessment of the state of carbohydrate metabolism in patients with polycystic ovary syndrome are considered. The regimens of treatment with antiandrogens and the expediency of their use in patients with polycystic ovary of endocrine origin are discussed.

Article Details

How to Cite
Mykytyuk, M., and O. Khyzhnyak. “Hyperandrogenism Syndrome: Diagnostics and Treatment from the Position of Clinical Endocrinology”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 8, Aug. 2021, pp. 662-8, doi:10.22141/2224-0721.16.8.2020.222887.
Section
Literature Review

References

Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. doi: 10.1038/nrdp.2016.57.

Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Hormone-modulating therapies for skin disease. J Am Acad Dermatol. 2019 Jun;80(6):1509-1521. doi: 10.1016/j.jaad.2018.08.061.

Tronko MD, Kaminsky VV, Tatarchuk TF, Dubossarskaya YO. National consensus on the management of patients with hyperandrogenism. Reproductive endocrinology. 2016;(30):3-13. doi: 10.18370/2309-4117.2016.30.8-18. (in Ukrainian).

Matheson E, Bain J. Hirsutism in Women. Am Fam Physician. 2019 Aug 1;100(3):168-175.

Pfieffer ML. Polycystic ovary syndrome: An update. Nursing. 2019 Aug;49(8):34-40. doi: 10.1097/01.NURSE.0000569748.65796.d1.

Raperport C, Homburg R. The Source of Polycystic Ovarian Syndrome. Clin Med Insights Reprod Health. 2019 Sep 3;13:1179558119871467. doi: 10.1177/1179558119871467.

Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020 Mar;502:214-221. doi: 10.1016/j.cca.2019.11.003.

Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publikation; 1992. 377-384 pp.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.

Peña AS, Witchel SF, Hoeger KM, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020 Mar 24;18(1):72. doi: 10.1186/s12916-020-01516-x.

Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6.

Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017 Sep;108(3):426-441. doi: 10.1016/j.fertnstert.2017.06.026.

Broux E, Dewailly D, Catteau-Jonard S. Spironolactone as a relay for cyproterone acetate in hyperandrogenic women. Gynecol Obstet Fertil Senol. 2020 Feb;48(2):181-186. French. doi: 10.1016/j.gofs.2020.01.001.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012.

Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 2019 Nov 1;236:116940. doi: 10.1016/j.lfs.2019.116940.

Semenyna GB, Pankiv VI, Pashkovska NV, Korutko OO, Pankiv IV. Ovarian factors in the pathogenesis of chronic anovulation in polycystic ovary syndrome. Problems of endocrine pathology. 2020;1:65-71. doi:10.21856/j-PEP.2020.1.09. (in Ukrainian).

Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019 Jun 14;3(8):1545-1573. doi: 10.1210/js.2019-00078.

Lawrence EJ. The clinical presentation of Ehlers-Danlos syndrome. Adv Neonatal Care. 2005 Dec;5(6):301-14. doi: 10.1016/j.adnc.2005.09.006.

Castori M. Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations. ISRN Dermatol. 2012;2012:751768. doi: 10.5402/2012/751768.

O'Connor S, Kim ESh, Brinza E, et al. Systemic connective tissue features in women with fibromuscular dysplasia. Vasc Med. 2015 Oct;20(5):454-62. doi: 10.1177/1358863X15592192.